Figure 1 Changes in relative plasma volume (RPV)

Slides:



Advertisements
Similar presentations
How best to control salt overload in hypertension? - Dietetic? - Aligning dialysate sodium with patient's serum sodium -Prohibition of sodium profiling.
Advertisements

LONG TERM BLOOD PRESSURE MONITORING J. Dušek 1, B. Fišer 1, J. Siegelová 1, P. Vank 1, G. Cornelissen 2, F. Halberg 2 1 Masaryk University, Brno 2 Halberg.
Ultrafiltration Control using Hematocrit Monitoring 2013 ANNA North Carolina Statewide Symposium and the Southeastern Kidney Council NC Annual Meeting.
Concept of dry weight in haemodialysis. Introduction   Achieving and maintaining dry-weight appears to be An effective but forgotten strategy in Controlling.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.
Acid-base profile in patients on PD
A.M. Thompson, T.G. Pickering  Kidney International 
Copyright © 2010 American Medical Association. All rights reserved.
Thomas G. Pickering, MD, DPhil, William B. White, MD 
Eoin O’Brien, DSc, MD, Eamon Dolan, MD, FRCPI  Clinical Therapeutics 
BEAUTY Trial: Hypertension Control Not Improved with Hemodynamic Monitoring From ESH 2016 | LB 3: Pierre Boutouyrie, MD, PhD INSERM, Université Paris Descartes,
Volume 55, Issue 2, Pages (February 1999)
Intensive Hemodialysis: Applied Clinical Practice
Iron indices: What do they really mean?
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Plasma sodium and hypertension
Figure 6 Effects of adiponectin on podocyte function
Linear and logistic regression analysis
Section VIII. Ambulatory BP Measurement
Buffer transport in peritoneal dialysis
Figure 4 Effect of dapagliflozin on HbA1c and body weight
New options for the anemia of chronic kidney disease
Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Nephrol. doi: /nrneph
Figure 7 The efficacy of phosphate-binder therapy
Acid-base profile in patients on PD
Figure 2 Expression of complement activation products in renal samples
Managing Patients With Transient Ischemic Attack
Section 2: AKI Definition
Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.
Figure 1 Acute kidney injury and chronic kidney disease
Volume 93, Issue 1, Pages (January 2018)
Fluid Management in Adults and Children: Core Curriculum 2014
Nat. Rev. Nephrol. doi: /nrneph
Figure 6 Hypothetical effect of starting therapy for autosomal
Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real?  S. Andrulli, S. Di Filippo, F. Locatelli 
M. Kraemer, C. Rode, V. Wizemann  Kidney International 
Overcoming barriers that inhibit proper treatment of anemia
Nat. Rev. Nephrol. doi: /nrneph
Volume 55, Issue 2, Pages (February 1999)
Volume 69, Issue 2, Pages (January 2006)
Prediction of hypertension in chronic hemodialysis patients
Figure 2 Sources of data to characterize the ADPKD clinical phenotype
Volume 53, Issue 4, Pages (April 1998)
Proinflammatory effects of iron sucrose in chronic kidney disease
Figure 1 Patient, facility, health-care system and industry factors
Blood pressure targets in hemodialysis patients
Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation?  Pantelis A. Sarafidis, Luis.
Volume 62, Issue 3, Pages (September 2002)
Volume 65, Issue 5, Pages (May 2004)
The dynamics of prognostic indicators: toward earlier identification of dialysis patients with a high risk of dying  Charles Chazot, Guillaume Jean  Kidney.
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
SYMPLICITY: not all that simple
Volume 61, Issue 1, Pages (January 2002)
Volume 62, Issue 4, Pages (October 2002)
Nina Vasavada, Chandan Saha, Rajiv Agarwal  Kidney International 
Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels in dialysis patients. Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels.
Volume 71, Issue 9, Pages (May 2007)
Figure 8 Assessment of colonic tone using a barostat device
Role of sodium in hemodialysis
Hector J. Rodriguez, Regina Domenici, Anne Diroll, Irina Goykhman 
Estimated daily P intake (in mg/d) from daily protein intake (in g/d) in 107 MHD patients from the NIED Study (30). Estimated daily P intake (in mg/d)
Decision-Making in Patients With Cancer and Kidney Disease
Gentamicin plasma and peritoneal dialysate concentrations in peritoneal dialysis patients with peritonitis. Gentamicin plasma and peritoneal dialysate.
Changes in 44-hour interdialytic systolic BP as a function of change in echocardiographic volume parameter. Changes in 44-hour interdialytic systolic BP.
Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.
Aliskiren, the orally effective renin inhibitor, provides antihypertensive efficacy at least equivalent to the ARB irbesartan in patients with hypertension.
Forest plot shows the risk ratio of masked hypertension (among clinic normotension) to white-coat hypertension (among clinic hypertension). Forest plot.
Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.
Presentation transcript:

Figure 1 Changes in relative plasma volume (RPV) in response to reductions in dry weight in a patient on dialysis Figure 1 | Changes in relative plasma volume (RPV) in response to reductions in dry weight in a patient on dialysis. Despite the use of four antihypertensive medications, the patient's mean interdialytic ambulatory blood pressure at baseline was 149/89 mmHg. RPV monitoring at baseline revealed no change in intravascular blood volume during dialysis (flat slope), indicating extracellular volume expansion. After 8 weeks of dry-weight probing, a 2.0 kg reduction in postdialysis weight was observed; RPV monitoring at 8 weeks revealed a 3.15% decrease in RPV per hour during dialysis. Mean 44 h ambulatory blood pressure was reduced by 24/12 mmHg at this time point. Permission obtained from the American Society of Nephrology © Agarwal, R. & Weir, M. Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in haemodialysis patients. Clin. J. Am. Soc. Nephrol. 5, 1255–1260 (2010). Permission obtained from the American Society of Nephrology © Agarwal, R. & Weir, M. Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in haemodialysis patients. Clin. J. Am. Soc. Nephrol. 5, 1255–1260 (2010). Georgianos, P. I. & Agarwal, R. (2016) Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.129